Rhumbline Advisers grew its holdings in Luminex Co. (NASDAQ:LMNX) by 20.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 127,244 shares of the medical instruments supplier’s stock after purchasing an additional 21,573 shares during the period. Rhumbline Advisers owned approximately 0.29% of Luminex worth $2,941,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of LMNX. Bank of Montreal Can boosted its position in Luminex by 542.7% during the third quarter. Bank of Montreal Can now owns 8,316 shares of the medical instruments supplier’s stock valued at $252,000 after purchasing an additional 7,022 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Luminex by 81.4% during the third quarter. Russell Investments Group Ltd. now owns 262,184 shares of the medical instruments supplier’s stock valued at $7,882,000 after purchasing an additional 117,685 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Luminex during the third quarter valued at $2,291,000. US Bancorp DE boosted its position in Luminex by 4,090.5% during the third quarter. US Bancorp DE now owns 11,063 shares of the medical instruments supplier’s stock valued at $335,000 after purchasing an additional 10,799 shares during the last quarter. Finally, Wedge Capital Management L L P NC boosted its position in Luminex by 18.3% during the third quarter. Wedge Capital Management L L P NC now owns 17,827 shares of the medical instruments supplier’s stock valued at $540,000 after purchasing an additional 2,756 shares during the last quarter. 84.56% of the stock is currently owned by institutional investors.
NASDAQ LMNX opened at $23.98 on Monday. Luminex Co. has a fifty-two week low of $19.20 and a fifty-two week high of $35.37. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of 49.96, a P/E/G ratio of 5.58 and a beta of 0.79.
Luminex (NASDAQ:LMNX) last posted its quarterly earnings data on Monday, February 4th. The medical instruments supplier reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.08). The business had revenue of $81.10 million during the quarter, compared to the consensus estimate of $80.76 million. Luminex had a return on equity of 4.61% and a net margin of 5.81%. The company’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.20 earnings per share. On average, equities research analysts anticipate that Luminex Co. will post 0.29 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 11th. Stockholders of record on Thursday, March 21st will be paid a $0.06 dividend. The ex-dividend date is Wednesday, March 20th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.00%. Luminex’s payout ratio is presently 50.00%.
Several equities analysts have weighed in on the company. ValuEngine lowered Luminex from a “strong-buy” rating to a “buy” rating in a report on Friday, December 21st. TheStreet lowered Luminex from a “b-” rating to a “c+” rating in a report on Friday, December 14th. BidaskClub lowered Luminex from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Finally, Zacks Investment Research lowered Luminex from a “hold” rating to a “sell” rating in a report on Friday, January 18th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $28.40.
Luminex Profile
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.